Company news

Codexis, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Codexis Announces Appointment of Rahul Singhvi, Sc.D., to Board of Directors

October 2, 2022

Codexis Announces Appointment of Kevin Norrett as Chief Operating Officer

October 2, 2022

Codexis’ 2022 Protein Engineering Forum Showcases Recent Industry Success and Emerging Innovations in the Field

September 13, 2022

Codexis Reports Second Quarter 2022 Financial Results

August 3, 2022

Codexis and Molecular Assemblies Announce Execution of Commercial License and Enzyme Supply Agreement for Optimized TdT Enzyme for Enzymatic DNA Synthesis

August 1, 2022

Codexis Announces CEO Transition Effective August 9, 2022

July 17, 2022

Codexis Announces Preliminary Second Quarter 2022 Results and Updates Guidance

July 13, 2022

Codexis Announces Agreement with Pfizer to Supply Enzyme for the Manufacture of PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets)

July 13, 2022

Codexis Announces the Publication of Research Demonstrating Proof of Concept for Chemoenzymatic Site-Selective Bioconjugation of Native Peptides

June 16, 2022

Codexis Presents Pre-Clinical Data Highlighting Gene Therapy Programs at the ASGCT 25th Annual Meeting

May 15, 2022

Codexis Reports First Quarter 2022 Financial Results

May 4, 2022

Codexis to Present Data Highlighting Three Gene Therapy Programs at the ASGCT 25th Annual Meeting

May 1, 2022

Codexis to Report First Quarter 2022 Financial Results on May 5

April 20, 2022

Codexis and seqWell Announce Strategic Investment and Partnership Initiation

April 20, 2022

Codexis and Molecular Assemblies Announce Results of First Collaboration on a Proprietary High Performing DNA Polymerase to Supercharge Fully Enzymatic DNA Synthesis

April 11, 2022

Codexis to Participate in the Cowen 42nd Annual Health Care Conference

February 28, 2022

Codexis Reports Fourth Quarter and Fiscal Year 2021 Financial Results

February 23, 2022

Codexis to Report Fourth Quarter and Fiscal Year 2021 Financial Results on February 24

February 9, 2022

Codexis Announces FDA Orphan Drug and Rare Pediatric Disease Designations for CDX 6512 for the Treatment of Homocystinuria

January 23, 2022

Codexis to Participate in the H.C. Wainwright Virtual BioConnect Conference

January 4, 2022

Codexis Launches Codex® HiTemp Reverse Transcriptase to Address Key Challenges in One-Step Assays for RNA Detection in PCR Testing, including COVID-19 Testing

December 14, 2021

Codexis Presents Pre-Clinical Data Highlighting its Programs in Homocystinuria and Maple Syrup Urine Disease at ICIEM 2021

November 21, 2021

Codexis to Participate in Upcoming Virtual Healthcare Conferences

November 18, 2021

Codexis to Present Data Highlighting Two New Therapeutic Discovery Programs at the 14th International Congress of Inborn Errors of Metabolism 2021

November 14, 2021

Codexis Appoints Two New Senior Leaders for Human Resources and Corporate Development

November 14, 2021

The SynBio Innovation Accelerator, a Collaboration between Codexis and Casdin Capital, Enables $10 million Investment in Molecular Assemblies, Inc.

November 3, 2021

Codexis Reports Third Quarter 2021 Financial Results

November 3, 2021

Codexis and Nestlé Health Science Initiate a Phase 1 Clinical Trial of CDX-7108 for Exocrine Pancreatic Insufficiency

November 2, 2021

Codexis to Report Third Quarter 2021 Financial Results on November 4

October 20, 2021

Codexis, Almelo and RC2 Announce a Tri-Party Collaboration for the Enzymatic Production of Low Cost Sitagliptin API for the Generic Market, Including a License to Codexis Enzyme Technology in India

October 17, 2021

Codexis and Merck Amend and Extend Supply Agreement for Enzyme Used in Manufacture of Sitagliptin

September 8, 2021

Codexis Confirms Receipt of Follow-on Orders for Proprietary Enzyme Product from Undisclosed Global Pharmaceutical Company

August 24, 2021

Codexis Reports Second Quarter 2021 Financial Results

August 4, 2021

Codexis and Kalsec Announce Expanded Collaboration for Supply of Novel Enzyme to Sustainably Produce Natural Clean-Label Beverage Ingredient

August 1, 2021

Codexis and Kalsec Announce Expanded Collaboration for Supply of Novel Enzyme to Sustainably Produce Natural Clean-Label Beverage Ingredient

July 25, 2021

Codexis to Report Second Quarter 2021 Financial Results on August 5

July 21, 2021

Codexis Announces Completion of CodeEvolver® License Technology Transfer with Global Pharmaceutical Leader

July 13, 2021

Codexis Earns Milestone Payment from GlaxoSmithKline

July 6, 2021

Codexis Raises 2021 Guidance Following Receipt of Significant New Order for a Proprietary Enzyme Product

June 16, 2021

Codexis and Takeda Expand Strategic Collaboration and License Agreement to Discover Additional Gene Therapy for a Fourth Rare Genetic Disorder

June 9, 2021

Codexis Reports First Quarter 2021 Financial Results

May 5, 2021

Codexis to Report First Quarter 2021 Financial Results on May 6

April 21, 2021

Codexis Reports Fourth Quarter and Fiscal Year 2020 Financial Results

February 24, 2021

Codexis to Present at Upcoming Virtual Healthcare Conferences

February 17, 2021

Codexis to Report Fourth Quarter and Full Year 2020 Results on February 25

February 10, 2021

Codexis Announces Expansion to New Facility to Accommodate Next Stage of Growth

February 8, 2021

Codexis Appoints Dr. Esther Martinborough to its Board of Directors

February 2, 2021

Codexis Introduces Improved Enzymes to Further Enhance Tate & Lyle's Stevia and Allulose Production

January 12, 2021

Codexis Announces Proposed Public Offering of Common Stock

December 1, 2020

Codexis Announces Pricing of Public Offering of Common Stock

December 1, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 18 calls. Every call is listed under its year.

Decks

The 5 newest of 24 decks. Every deck is listed under its year.